Once the cen­ter of a pub­lic storm of anger over de­nied drug, Chimerix now can’t even re­cruit pa­tients for their tri­als

Five years af­ter Chimerix found it­self at the cen­ter of a hur­ri­cane of pub­lic anger over its ini­tial re­fusal to pro­vide their lead ex­per­i­men­tal drug to a dy­ing child, the biotech says now that they can’t even re­cruit pa­tients for their stud­ies. 

That’s forc­ing them to scrap all their late-stage clin­i­cal de­vel­op­ment work on the drug — the oral an­tivi­ral brin­cid­o­fovir — and lay off half the re­main­ing staff at the Durham, NC-based biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.